endometrial neoplasms

Summary

Summary: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.

Top Publications

  1. Umene K, Banno K, Kisu I, Yanokura M, Nogami Y, Tsuji K, et al. New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review). Oncol Rep. 2013;29:855-60 pubmed publisher
    ..In this study, we review the background and early clinical evidence for these agents as new therapeutic candidates for endometrial cancer. ..
  2. Lee C, Ali R, Rouzbahman M, Mariño Enríquez A, Zhu M, Guo X, et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012;36:1562-70 pubmed
    ..When evaluating high-grade uterine sarcomas, cyclin D1 can be included in the immunohistochemical panel as an indicator of YWHAE-FAM22 ESS. ..
  3. Wu L, Xu J, Gu H, Hua J, Haacke E, Hu J. Predictive value of T2-weighted imaging and contrast-enhanced MR imaging in assessing myometrial invasion in endometrial cancer: a pooled analysis of prospective studies. Eur Radiol. 2013;23:435-49 pubmed publisher
    ..But its PPV is somewhat suboptimal. For assessing deep myometrial involvement, its NPV appears relative high and negative findings strongly suggest an absence of deep myometrial involvement, which can guide therapeutic decision-making. ..
  4. Salvesen H, Haldorsen I, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13:e353-61 pubmed publisher
    ..We summarise the present knowledge regarding biomarkers in endometrial carcinoma, assessing how such markers could be applied to address key clinical challenges for the treatment of this disease. ..
  5. Friedenreich C, Langley A, Speidel T, Lau D, Courneya K, Csizmadi I, et al. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer. 2012;19:785-92 pubmed publisher
    ..Interventions aimed at decreasing both obesity and insulin resistance may decrease endometrial cancer risk. ..
  6. Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol. 2012;24:554-63 pubmed publisher
  7. Wik E, Ræder M, Krakstad C, Trovik J, Birkeland E, Hoivik E, et al. Lack of estrogen receptor-? is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res. 2013;19:1094-105 pubmed publisher
    ..We present a rationale for investigating ER-?'s potential to predict response to PI3K/mTOR inhibitors in clinical trials and also suggest EMT inhibitors to ER-?-negative endometrial carcinomas. ..
  8. Matsuo K, Gray M, Yang D, Srivastava S, Tripathi P, Sonoda L, et al. The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival. Gynecol Oncol. 2013;128:552-9 pubmed publisher
    ..Our results demonstrate, for the first time, that the GRP78 levels in endometrial cancer patients may be a prognosticator and aid with clinical risk stratification and focused surveillance. ..
  9. Mitsuhashi Y, Horiuchi A, Miyamoto T, Kashima H, Suzuki A, Shiozawa T. Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells. Histopathology. 2012;60:826-37 pubmed publisher
    ..The Notch1-JAG1 axis may enhance the invasive properties of endometrial carcinomas, which suggests the Notch pathway may be a promising target for the treatment of this malignancy. ..

More Information

Publications77

  1. Fedirko V, Jenab M, Rinaldi S, Biessy C, Allen N, Dossus L, et al. Alcohol drinking and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Ann Epidemiol. 2013;23:93-8 pubmed publisher
    ..Our findings suggest no association between alcohol intake and endometrial cancer risk. ..
  2. Erkanli S, Bolat F, Seydaoglu G. Detection and importance of micrometastases in histologically negative lymph nodes in endometrial carcinoma. Eur J Gynaecol Oncol. 2011;32:619-25 pubmed
    ..The finding of micrometastases can change therapeutic decisions for the better by incorporating adjuvant treatment options. ..
  3. Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, et al. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS ONE. 2012;7:e52795 pubmed publisher
    ..Our results emphasize the potential for targeting FGFR2, KRAS and PIK3CA mutations in endometrial cancer for development of novel therapeutic strategies. ..
  4. Chattopadhyay S, Cross P, Nayar A, Galaal K, Naik R. Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer. Int J Gynecol Cancer. 2013;23:690-7 pubmed publisher
    ..Tumor size could play a significant role in risk stratification and planning adjuvant treatment in women with International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer. ..
  5. Alhilli M, Podratz K, Dowdy S, Bakkum Gamez J, Weaver A, McGree M, et al. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol. 2013;128:294-9 pubmed publisher
    ..HR and IR patients combined (3/4 of population) have a substantial risk of LN+ or LNRec (17%). Lymphadenectomy is proposed to be advantageous in HR and IR patients if accurate frozen section is lacking. ..
  6. Todo Y, Watari H, Okamoto K, Hareyama H, Minobe S, Kato H, et al. Tumor volume successively reflects the state of disease progression in endometrial cancer. Gynecol Oncol. 2013;129:472-7 pubmed publisher
    ..Tumor volume successively reflects the state of disease progression in endometrial cancer. The volume index can give information on both the staged prognosis and surgical management. ..
  7. Hu Q, Yu L, Chen R, Wang Y, Ji L, Zhang Y, et al. 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy. Int J Gynecol Cancer. 2012;22:951-9 pubmed publisher
    ..5-Aza-2'-deoxycytidine and MPA synergistically inhibit EC cell growth and invasion. Their combined use may provide a new effective therapeutic opportunity for endometrial carcinoma. ..
  8. Capobianco G, Pili F, Contini M, De Miglio M, Marras V, Santeufemia D, et al. Analysis of epidermal growth factor receptor (EGFR) status in endometrial stromal sarcoma. Eur J Gynaecol Oncol. 2012;33:629-32 pubmed
    ..The aim of this study was to analyze EGFR status in an ESS series and to evaluate their potential role as molecular targets...
  9. Jakate K, Azimi F, Ali R, Lee C, Clarke B, Rasty G, et al. Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors. Mod Pathol. 2013;26:95-105 pubmed publisher
    ..Our data do not show any difference in clinical behavior between subgroups in undifferentiated sarcomas...
  10. Subramaniam K, Tham S, Mohamed Z, Woo Y, Mat Adenan N, Chung I. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLoS ONE. 2013;8:e68923 pubmed publisher
  11. Kisu I, Banno K, Lin L, Ueno A, Abe T, Kouyama K, et al. Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer: comparison of magnetic resonance imaging and frozen sections. Acta Obstet Gynecol Scand. 2013;92:525-35 pubmed publisher
    ..To compare the diagnostic characteristics of the evaluation of myometrial invasion (MI) retrospectively between preoperative magnetic resonance imaging (MRI) and intraoperative frozen sections...
  12. Krakstad C, Trovik J, Wik E, Engelsen I, Werner H, Birkeland E, et al. Loss of GPER identifies new targets for therapy among a subgroup of ER?-positive endometrial cancer patients with poor outcome. Br J Cancer. 2012;106:1682-8 pubmed publisher
    ..Our purpose was to investigate the potential of GPER as a prognostic and predictive marker in endometrial carcinoma and to search for new drug candidates to improve treatment of aggressive disease...
  13. Matias Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013;62:111-23 pubmed publisher
    ..Understanding pathogenesis at the molecular level is essential for identifying biomarkers of potential use in targeted therapies...
  14. Feng W, Hua K, Malpica A, Zhou X, Baak J. Stages I to II WHO 2003-defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough?. Int J Gynecol Cancer. 2013;23:488-93 pubmed publisher
    ..However, primary treatment practices range from limited surgery only to extensive surgery combined with adjuvant chemotherapy and radiotherapy. We focused on the primary treatment of early-stage WHO 2003-defined low-grade ESS...
  15. Lundin E, Wirgin I, Lukanova A, Afanasyeva Y, Krogh V, Axelsson T, et al. Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer. Cancer Epidemiol. 2012;36:445-52 pubmed publisher
    ..The role of estrogen and progesterone in the development of endometrial cancer is well documented. Few studies have examined the association of genetic variants in sex hormone-related genes with endometrial cancer risk...
  16. McConechy M, Ding J, Cheang M, Wiegand K, Senz J, Tone A, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20-30 pubmed publisher
    ..If used in practice, it may lead to improved diagnostic reproducibility and may also serve to stratify patients for targeted therapeutics...
  17. Chen C, Wang S, Chen C, Huang M, Hung J, Huang H, et al. MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer. Gynecol Oncol. 2013;128:560-7 pubmed publisher
    ..Mucins play a critical role in the malignancy of various tumors and have been identified as diagnostic markers and as attractive therapeutic targets. However, the role of mucin (MUC) 20 in endometrial cancer (EC) is still unknown...
  18. Feng W, Malpica A, Robboy S, Gudlaugsson E, Hua K, Zhou X, et al. Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. Int J Gynecol Pathol. 2013;32:299-306 pubmed publisher
    ..00001, hazard ratio=45.4). When strictly defined microscopic criteria are used, the WHO 2003 diagnoses of ESS, low grade and UES are well reproducible and prognostically strong...
  19. Kusunoki S, Kato K, Tabu K, Inagaki T, Okabe H, Kaneda H, et al. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecol Oncol. 2013;129:598-605 pubmed publisher
    ..We also assessed the effects of salinomycin (a compound with EMT-specific toxicity) on the proliferative capacity, migration and invasiveness of these endometrial CSCs using Hec1-SP cells...
  20. Boren T, Lea J, Kehoe S, Miller D, Richardson D. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. Gynecol Oncol. 2012;127:43-6 pubmed publisher
    ..The aim of this study was to determine the risk of lymphatic metastasis in patients with endometrial cancers with occult tumor extension to the uterine cervix...
  21. Jedryka M, Chrobak A, Chelmonska Soyta A, Gawron D, Halbersztadt A, Wojnar A, et al. Matrix metalloproteinase (MMP)-2 and MMP-9 expression in tumor infiltrating CD3 lymphocytes from women with endometrial cancer. Int J Gynecol Cancer. 2012;22:1303-9 pubmed
    ..Further studies explaining the role of tumor infiltrating lymphocytes in mediating the endometrial cancer milieu are needed. ..
  22. Bao W, Wang H, Tian F, He X, Qiu M, Wang J, et al. A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer. 2013;12:155 pubmed publisher
  23. Yi T, Li J, Han X, Guo J, Qu Q, Guo L, et al. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo. Chemotherapy. 2012;58:19-29 pubmed publisher
    ..The effect of histone deacetylase inhibitors (HDACIs) and DNA methyltransferase inhibitors (DNMTIs) on proliferation of endometrial cancer (EC) cells in vitro and in vivo was investigated...
  24. Feng W, Hua K, Gudlaugsson E, Yu Y, Zhou X, Baak J. Prognostic indicators in WHO 2003 low-grade endometrial stromal sarcoma. Histopathology. 2013;62:675-87 pubmed publisher
    ..Since 2003, many studies have used the old criteria, and few have focused on WHO 2003-defined ESS low grade (ESS-LG). The aim of this study was to investigate prognosticators in ESS-LG...
  25. Lee C, Mariño Enríquez A, Ou W, Zhu M, Ali R, Chiang S, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36:641-53 pubmed publisher
    ..Thus, their distinction from typical JAZF1 ESS is important for prognostic and therapeutic purposes...
  26. Byron S, Gartside M, Powell M, Wellens C, Gao F, Mutch D, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE. 2012;7:e30801 pubmed publisher
    ..This has implications for the implementation of anti-FGFR or anti-MEK biologic therapies...
  27. Yeramian A, Moreno Bueno G, Dolcet X, Catasus L, Abal M, Colas E, et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32:403-13 pubmed publisher
    ..In this review, the genetic changes of endometrial carcinogenesis are discussed in the light of the morphological features of the tumors and their precursors...
  28. Antonsen S, Loft A, Fisker R, Nielsen A, Andersen E, Høgdall E, et al. SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. Gynecol Oncol. 2013;129:298-303 pubmed publisher
    ..To evaluate SUVmax in the assessment of endometrial cancer preoperatively with particular focus on myometrial invasion (MI), cervical invasion (CI), FIGO stage, risk-stratification and lymph node metastases (LNM)...
  29. Kumar S, Medeiros F, Dowdy S, Keeney G, Bakkum Gamez J, Podratz K, et al. A prospective assessment of the reliability of frozen section to direct intraoperative decision making in endometrial cancer. Gynecol Oncol. 2012;127:525-31 pubmed publisher
    ..To determine the reliability of intraoperative frozen sections (IFSs) for surgical staging of endometrial cancer (EC)...
  30. Setiawan V, Yang H, Pike M, McCann S, Yu H, Xiang Y, et al. Type I and II endometrial cancers: have they different risk factors?. J Clin Oncol. 2013;31:2607-18 pubmed publisher
    ..The results of this pooled analysis suggest that the two endometrial cancer types share many common etiologic factors. The etiology of type II tumors may, therefore, not be completely estrogen independent, as previously believed. ..
  31. Hill E, Dizon D. Medical therapy of endometrial cancer: current status and promising novel treatments. Drugs. 2012;72:705-13 pubmed publisher
    ..Recent interest in the molecular pathways of carcinogenesis have lead to increased investigation of these novel agents and the hope that they will impact positively on the overall survival of women with endometrial cancer...
  32. Dong L, Zhou Q, Zhang Z, Zhu Y, Duan T, Feng Y. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res. 2012;38:1077-85 pubmed publisher
    ..This study aimed to investigate the effect of metformin on endometrial cancer cell chemotherapeutic sensitivity and explore the underlying molecular mechanisms...
  33. Kim H, Kim T, Song T, Kim M, Lee Y, Choi C, et al. Patterns of recurrence in endometrial cancer patients at risk of lymph node metastasis or recurrence according to extent of lymphadenectomy. Int J Gynecol Cancer. 2012;22:611-6 pubmed publisher
    ..The purpose of this study was to compare the patterns of recurrence in patients with risk of lymph node (LN) metastasis or recurrence according to the extent of lymphadenectomy (LND)...
  34. Slomovitz B, Coleman R. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18:5856-64 pubmed publisher
    ..Clinical validation of these findings is ongoing...
  35. Bischoff J, Ignatov A, Semczuk A, Schwarzenau C, Ignatov T, Krebs T, et al. hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis. 2012;29:889-900 pubmed publisher
    ..These findings may have importance for the specific chemosensitization of the primary tumors/metastases and can improve our understanding of endometrial carcinogenesis in humans...
  36. Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, et al. Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review). Int J Oncol. 2012;40:1755-62 pubmed publisher
    ..This drug is expected to be clinically applicable as a new drug for the treatment of endometrial cancer...
  37. Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, et al. Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics. 2012;4:147-62 pubmed publisher
    ..Identification of such disease-related genes may contribute to early detection and prevention of endometrial cancer...
  38. Long J, Zheng W, Xiang Y, Lose F, Thompson D, Tomlinson I, et al. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:980-7 pubmed publisher
    ..Genome-wide association studies (GWAS) have identified more than 100 genetic loci for various cancers. However, only one is for endometrial cancer...
  39. Kolbe D, DeLoia J, Porter Gill P, Strange M, Petrykowska H, Guirguis A, et al. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS ONE. 2012;7:e32941 pubmed publisher
    ..Our finding of differences between serous and endometrioid ovarian tumors indicates that intervention strategies could be developed to specifically address subtypes of epithelial ovarian cancer...
  40. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, et al. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer. 2013;132:1633-45 pubmed publisher
    ..909 (95% CI: 0.789-973) and 0.913 (95% CI: 0.794-0.976), respectively. We conclude that miRNA signatures hold a great promise to become noninvasive biomarkers for early EEC detection and prognosis...
  41. Yildiz A, Yetimalar H, Kasap B, Aydin C, Tatar S, Soylu F, et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2012;164:191-5 pubmed publisher
    ..To evaluate whether a preoperative serum CA-125 level in patients with endometrial carcinoma can provide additional information in determining the stage of disease, and which cutoff value is optimal in this respect...
  42. Antonsen S, Jensen L, Loft A, Berthelsen A, Costa J, Tabor A, et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. Gynecol Oncol. 2013;128:300-8 pubmed publisher
    ..The aim of this prospective multicenter study was to evaluate and compare the diagnostic performance of PET/CT, MRI and transvaginal two-dimensional ultrasound (2DUS) in the preoperative assessment of endometrial cancer (EC)...
  43. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS ONE. 2012;7:e37431 pubmed publisher
    ..Our data suggest that mutational statuses of PTEN and K-Ras might be useful predictors of sensitivity to NVP-BEZ235 in certain endometrial carcinomas...
  44. Cossu Rocca P, Contini M, Uras M, Muroni M, Pili F, Carru C, et al. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis. Int J Gynecol Pathol. 2012;31:570-9 pubmed publisher
    ..Specific post-translational abnormalities, responsible for activation of TKRs, should be further investigated...
  45. Yasuda M, Katoh T, Hori S, Suzuki K, Ohno K, Maruyama M, et al. Endometrial intraepithelial carcinoma in association with polyp: review of eight cases. Diagn Pathol. 2013;8:25 pubmed publisher
    ..The uterine endometrial polyp (EMP) has a potential risk of developing malignant tumors especially in postmenopausal women. These malignancies include endometrial intraepithelial carcinoma (EIC)...
  46. Todo Y, Choi H, Kang S, Kim J, Nam J, Watari H, et al. Clinical significance of tumor volume in endometrial cancer: a Japan-Korea cooperative study. Gynecol Oncol. 2013;131:294-8 pubmed publisher
    ..The aim of this study was to elucidate the significance of tumor volume as a risk factor for predicting lymph node metastasis...
  47. Ichinose M, Fujimoto A, Osuga Y, Minaguchi T, Kawana K, Yano T, et al. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. Int J Gynecol Cancer. 2013;23:288-93 pubmed publisher
    ..However, on the other side, hyperestrogenic status caused by ovulation induction or controlled ovarian stimulation might promote the progression and the recurrence of the disease...
  48. Haldorsen I, Husby J, Werner H, Magnussen I, Rørvik J, Helland H, et al. Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists. Eur Radiol. 2012;22:1601-11 pubmed publisher
    ..To evaluate pelvic magnetic resonance imaging (MRI) interobserver agreement for the detection of deep myometrial invasion, cervical stroma invasion and lymph node metastases in endometrial carcinoma patients in relation to surgical staging...
  49. Laufer J, Scasso S, Papadia A, Sosa C, Cirillo F, Raspagliesi F. Association between tumor diameter and lymphovascular space invasion among women with early-stage endometrial cancer. Int J Gynaecol Obstet. 2013;123:142-5 pubmed publisher
    ..To investigate the association between tumor diameter and intratumoral risk factors that might predict the need for full surgical staging among women with endometrial cancer (EC)...
  50. Kim J, Kurita T, Bulun S. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34:130-62 pubmed publisher
    ..This review provides a unifying perspective for the diverse effects of progesterone across human tissues and diseases...
  51. Arem H, Neuhouser M, Irwin M, Cartmel B, Lu L, Risch H, et al. Omega-3 and omega-6 fatty acid intakes and endometrial cancer risk in a population-based case-control study. Eur J Nutr. 2013;52:1251-60 pubmed publisher
  52. Genkinger J, Friberg E, Goldbohm R, Wolk A. Long-term dietary heme iron and red meat intake in relation to endometrial cancer risk. Am J Clin Nutr. 2012;96:848-54 pubmed
    ..Heme and total iron, present in meat, have been hypothesized to promote carcinogenesis. Few prospective studies have examined the associations between intakes of heme and total iron, types of meat, and endometrial cancer risk...
  53. Dowdy S, Borah B, Bakkum Gamez J, Weaver A, McGree M, Haas L, et al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol. 2012;127:5-10 pubmed publisher
    ..Here we prospectively assess survival, sites of recurrence, morbidity, and cost in this low risk cohort...
  54. Banno K, Yanokura M, Kisu I, Yamagami W, Susumu N, Aoki D. MicroRNAs in endometrial cancer. Int J Clin Oncol. 2013;18:186-92 pubmed publisher
    ..In endometrial cancer, miRNAs are associated with regulation of gene expression, epigenetic dysfunction and carcinogenesis. Thus, miRNAs are likely to have key roles in diagnosis, prognostic prediction, and therapy in endometrial cancer...
  55. Haldorsen I, Stefansson I, Gruner R, Husby J, Magnussen I, Werner H, et al. Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. Br J Cancer. 2014;110:107-14 pubmed publisher
  56. Bendifallah S, Genin A, Naoura I, Chabbert Buffet N, Clavel Chapelon F, Haddad B, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207:197.e1-8 pubmed publisher
    ..Our objective was to develop a nomogram based on pathological hysterectomy characteristics to provide a more individualized and accurate estimation of lymph node metastasis in endometrial cancer...
  57. Bao W, Qiu H, Yang T, Luo X, Zhang H, Wan X. Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS ONE. 2013;8:e70616 pubmed publisher
    ..Our data support a novel function for TrkB in promoting EMT and resistance to anoikis. Thus, TrkB may constitute a potential therapeutic target in human EC. ..
  58. Trovik J, Wik E, Werner H, Krakstad C, Helland H, Vandenput I, et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer. 2013;49:3431-41 pubmed publisher
    ..We wanted to investigate if biomarkers could improve prediction of lymph node metastasis and outcome...
  59. Wild P, Ikenberg K, Fuchs T, Rechsteiner M, Georgiev S, Fankhauser N, et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med. 2012;4:808-24 pubmed publisher
  60. Koskas M, Bassot K, Graesslin O, Aristizabal P, Barranger E, Clavel Chapelon F, et al. Impact of lymphovascular space invasion on a nomogram for predicting lymph node metastasis in endometrial cancer. Gynecol Oncol. 2013;129:292-7 pubmed publisher
    ..The aim of this study was to evaluate the impact of lymphovascular space invasion (LVSI) on nomogram-based predictions of lymph node (LN) metastasis in endometrial cancer...
  61. Guinot J, Perez Calatayud J, Azcoaga J, Herruzo I, Bodineau C, Rovirosa A, et al. Consensus on treatment of endometrium carcinoma with brachytherapy. Clin Transl Oncol. 2012;14:263-70 pubmed publisher
    ..This article presents the consensus on treatment of endometrial carcinoma in operated (prophylactic vaginal BT) and unoperated (endouterine BT) patients...
  62. Lay V, Yap J, Sonderegger S, Dimitriadis E. Interleukin 11 regulates endometrial cancer cell adhesion and migration via STAT3. Int J Oncol. 2012;41:759-64 pubmed publisher
    ..This study shows a role for IL11 in endometrial cancer and suggests IL11 may be involved in endometrial cancer development and thus may be useful as a therapeutic target...
  63. Park J, Kim K, Nam J. Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma. Int J Gynecol Cancer. 2013;23:81-9 pubmed publisher
    ..To investigate potential therapeutic targets and prognostic markers for low-grade endometrial stromal sarcoma (LGESS)...
  64. Manohar M, Fatima I, Saxena R, Chandra V, Sankhwar P, Dwivedi A. (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation. J Nutr Biochem. 2013;24:940-7 pubmed publisher
    ..Taken together, these results suggest that EGCG inhibits cellular proliferation via inhibiting ERK activation and inducing apoptosis via ROS generation and p38 activation in endometrial carcinoma cells...
  65. Gifkins D, Olson S, Demissie K, Lu S, Kong A, Bandera E. Total and individual antioxidant intake and endometrial cancer risk: results from a population-based case-control study in New Jersey. Cancer Causes Control. 2012;23:887-95 pubmed publisher
    ..There was no strong evidence for an association with intake of any of the individual antioxidants. Our findings suggest that total phenolic consumption may decrease endometrial cancer risk...
  66. Peterson L, Kipp B, Halling K, Kerr S, Smith D, Distad T, et al. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. Int J Gynecol Pathol. 2012;31:195-205 pubmed publisher
    ..No BRAF V600E mutations were indentified. This study provides a comprehensive molecular genetic analysis of commonly analyzed targets in a large cohort of endometrial cancers...
  67. Alvarez T, Miller E, Duska L, Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?. Am J Surg Pathol. 2012;36:753-61 pubmed publisher
  68. Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martinez E, et al. The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol. 2012;14:715-20 pubmed publisher
    ..Pathways including progesterone receptor, TGF?, ETV5 and microRNAs are deeply related to the EMT process in EC...